Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 6/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 6/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23685064 | 0.81 | HRH3 (0.43) | HRH3CYP4F2CYP4A11CD274NOS3 | |
| SCHEMBL23684567 | 0.77 | ESR1 (0.48) | CYP4F2CYP4A11 | |
| SCHEMBL23683950 | 0.76 | HRH3 (0.50) | HRH3CD274NOS3NOS1NOS2 | |
| SCHEMBL22070632 | 0.71 | CYP4F2 (0.66) | CYP4F2CYP4A11 | |
| SCHEMBL8188548 | 0.69 | HRH3 (0.43) | HRH3CD274NOS3NOS1NOS2 | |
| SCHEMBL23684209 | 0.69 | HRH3 (0.51) | HRH3CD274NOS3NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL23684416 | 0.68 | HRH3 (0.50) | HRH3CD274NOS3NOS1NOS2 | |
| SCHEMBL23684595 | 0.67 | ALDH1A1 (0.38) | CYP4F2CYP4A11 | |
| SCHEMBL23684184 | 0.65 | CD274 (0.47) | HRH3CD274NOS3NOS1NOS2 | |
| SCHEMBL17585078 | 0.65 | HRH3 (0.58) | HRH3CD274NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11986471-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11986471-B2 | Compounds and methods of use | XDH, F12, LPXN | HRH3 183/4885CYP4F2 204/4885CYP4A11 66/4885 |
| US-11077101-B1 | Compounds and methods of use | XDH, F12, LPXN | HRH3 183/4885CYP4F2 204/4885CYP4A11 66/4885 |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | XDH, F12, LPXN | HRH3 183/4885CYP4F2 204/4885CYP4A11 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.